Key clinical point: Treatment with a combination of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAb) and onabotulinumtoxinA (onabot) was more effective than monotherapy with either anti-CGRP alone or onabot in reducing monthly migraine days (MMD) in patients with chronic migraine.
Major finding: Initiating therapy with either anti-CGRP mAbs or onabot significantly reduced the median MMD from 30 to 15 days, which further decreased to 8 days after initiating dual therapy with anti-CGRP mAb and onabot (both P < .0001). Overall, 68% of patients receiving dual therapy achieved 50% or greater reduction in MMD.
Study details : This real-world retrospective chart review included 423 patients with chronic migraine (age ≥ 18 years) who received monotherapy with either anti-CGRP mAb or onabot (n = 229) followed by dual therapy (concurrent treatment with anti-CGRP mAb and onabot; n = 194) for at least three consecutive months.
Disclosures: This study was funded by a Cleveland Clinic institutional grant. The authors declared no conflicts of interest.
Source: Salim A, Hennessy E, Sonneborn C, et al. Synergism of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in the treatment of chronic migraine: A real-world retrospective chart review. CNS Drugs. 2024 (Apr 7). doi: 10.1007/s40263-024-01086-z Source